Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Stress markers and social factors may affect how fast kidney disease progresses.
-
A large genetic study confirmed that SGLT2 inhibitors help protect both the heart and kidneys.
Today's news focuses on how external factors like stress and social status might impact kidney health. One study links high stress markers to faster kidney decline, while another looks at when disease is first found. A major genetic study also reinforced the protective benefits of SGLT2 inhibitors for the heart and kidneys.
SGLT2 inhibitors in chronic kidney disease.
This review summarizes major trials showing that SGLT2 drugs protect the kidneys. It covers both people with and without diabetes. The article also looks at how these drugs might help people on dialysis. It is a guide for doctors to feel confident starting this therapy for kidney care.
Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide.
This review combined data from many trials to check if semaglutide lowers the risk of dying from heart problems. It looked at people with type 2 diabetes, obesity, or kidney disease. The study found that semaglutide consistently reduces major heart events. This is important because heart disease is a top cause of death for people with kidney issues.
Disease-Targeted Therapies and eGFR Slope over 2 Years in IgA Nephropathy: A Systematic Review and Network Meta-Analysis
This review compared several new drugs for IgA nephropathy, a common cause of kidney failure. It analyzed large trials to see how well each drug slowed the drop in kidney filtering rate over two years. All the drugs tested helped slow decline, but the study did not find one clear winner. This is a preprint, so it has not yet passed full peer review.
Shared genetic architecture across fibrotic diseases
This large study found that scarring in different organs shares the same genetic roots. It looked at data from many large groups of people. It shows a link, not proof of cause.
Socioeconomic Inequities in Early Kidney Care Concentrate at Late Initial Clinical Detection Rather Than Planned Care: A Population-Based Study
This preprint studied how social and economic factors affect when kidney disease is first found in people in Scotland. It suggests that inequalities in care are most visible at the point of initial detection. This is an observational study, so it shows a link, not proof of cause. It is not yet peer-reviewed.
GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study.
This study compared two types of drugs in people with liver disease and heart failure. It used existing medical records to see which drug group had better outcomes. It is an observational study, so it shows a link but not proof of cause. The results may help doctors choose the right drug for complex patients.
GLP-1 Receptor Agonists and Cardiorenal Outcomes in Non-Obese, Non- Diabetic MASLD: A Propensity Score-Matched Study
This preprint studied people with liver disease who were not obese or diabetic. It looked at whether using GLP-1 drugs affected their heart and kidney health. It is an observational study, so it shows a link but not proof of cause. The results are not yet peer reviewed.
Association of Blood Glucose and Lipid Parameters with Increasing Albuminuria Severity in Patients with Type 2 Diabetes Mellitus
This study looked at 180 people with type 2 diabetes. It found a link between high blood sugar or cholesterol and more protein in the urine. This shows a connection, not proof of cause.
Clinical Profile and Predisposing Conditions of Culture-Confirmed Bacteriuria Among Adult Medical Inpatients with Pyuria: A Cross-Sectional Study in Bangladesh
This study described 100 hospitalized adults in Bangladesh who had bacteria in their urine. It looked at their symptoms and health conditions. It is an observational study, so it shows patterns but not proof of cause. It helps doctors understand who is at risk for these infections.
Study of Haematological Profile and Its Alterations in Patients with Chronic Kidney Disease Stages III–V on Conservative Management
This study looked at blood tests for people with advanced kidney disease. It found that blood abnormalities are common in these patients. This shows a link, not proof of cause.
Association between pro- and anti-inflammatory cytokines (IL-6, IL-10), hypothyroidism, and glomerular filtration rate in chronic kidney disease
This study looked at 100 men with kidney disease or low thyroid function. It found links between inflammation markers and kidney function. This shows a connection, not proof of cause.
Dysregulation of adipokines and inflammatory biomarkers in patients with metabolic syndrome and chronic kidney disease: A case-control study
Researchers compared 60 people with both metabolic syndrome and kidney disease to 60 healthy people. They found differences in blood markers for inflammation. This shows a link, not proof of cause.
Association of Anemia with Clinical, Laboratory, and Echocardiographic Characteristics in Patients with Heart Failure with Preserved Ejection Fraction: A Cross-Sectional Study
This study looked at 96 people with a type of heart failure. It found a link between low blood counts and heart health. This shows a connection, not proof of cause.
Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease
Older adults with kidney disease and high blood pressure who took a diabetes drug called dapagliflozin had less physical decline over one year. The study followed 135 people. It shows a link, not proof of cause.
Effect of combined sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonist therapy in patients with chronic kidney disease: a real-world analysis.
This study looked at real-world data for people with kidney disease. It compared using two types of diabetes drugs together versus using one alone. It tracked kidney and heart outcomes over two years. This is an observational study, so it shows a link, not proof of cause.
Hubungan Self Care Management dan Dukungan Keluarga Dengan Kualitas Hidup Pasien Chronic Kidney Disease (CKD) di Ruang Hemodialisis RSUD dr. Doris Sylvanus Palangka Raya
This study looked at how self-care and family support affect the quality of life for people on dialysis in Indonesia. It shows a link, not proof of cause.
End-Stage Kidney Disease of Unknown Etiology in Southern Iraq: Clinical Characteristics and a Distinct Cardiometabolic Profile Among Patients Receiving Maintenance Hemodialysis
In southern Iraq, many people have kidney failure with no clear cause. This study looked at 394 people on dialysis. It shows a link between this unknown cause and heart and metabolic issues, not proof of cause.
HNRNPC-mediated RNA processing promotes VHL-associated excessive vasculogenesis in von Hippel-Lindau syndrome revealed from patient-derived blood vessel models
This preprint used blood vessel models from patients to study a genetic condition called von Hippel-Lindau syndrome. It looked at how a specific gene affects the growth of blood vessels in the kidneys. This research was done in cells and models, not in people yet. It is not yet peer-reviewed.
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide.
Researchers created a new imaging tool to track how the drug tirzepatide moves through the body. They tested it in animals and found that the kidneys clear the drug, while the heart and liver take up some of it. This was done in animals, not people yet. It helps scientists understand where the drug goes.
cRGD engineered MSC-derived small extracellular vesicles as targeted delivery vehicles of miR-373 for liver fibrosis therapy
This study tested a new way to treat liver scarring using tiny bubbles from stem cells. It was in cells, not people yet.